Fibrinogen Consumption In Breast Cancer And Its Relation To The Extent And Type Of Metastases

1981 ◽  
Author(s):  
V Pengo ◽  
G Cartei ◽  
D Casara ◽  
C Guerra ◽  
E Bertaglia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Half Life ◽  
Fibrinogen Level ◽  
Degradation Products ◽  
Breast Cancer Patients ◽  
Normal Range ◽  
Fibrin Degradation Products ◽  
Extent Of Disease ◽  
Gelation Test

A subclinical intravascular coagulation-fibrinolysis syndrome (I.C.F.), is commonly present in cancer patients: a shortened fibrinogen halflife, in fact, have been found in most patients with malignancies, not considering, however, the type and extent of disease. 28 breast cancer patients, without bleeding and thromboembolic disorders and not receiving chemo-radiotherapy, have been assessed for the presence of I.C.F. syndrome by mean of radiofibrinogen half-life, fibrinogen level, ethanol gelation test, fibri- nogen/fibrin degradation products (FDP). 16 patients without metastases were studied before surgery, while 12 patients with metastases were studied after more than one month from the operation (7 diffuse metastases, 5 pulmonar metastases). 14 out of 16 patients of the first group, and 6 out of 7 with diffuse metastases showed a markedly shortened fibrinogen half-life (hours) (x=53.9±18.2, x=54.2±16.4 as mean±SD respectively), while all the patients with pulmonar metastases showed a normal fibrinogen half-life (x=84±9.9). Normal range was 73-91 h. FDP were almost always normal. In conclusion the tumor per se determine a fibrinogen consumption without a competent fibrinolysis. Pulmonar metastases don’t promote fibrinogen consumption and/or they don’t need fibrin for their growth and spread,

scholarly journals An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients

The Breast ◽  
2015 ◽  
Vol 24 (5) ◽  
pp. 667-672 ◽  
Author(s):  
Sabine Krenn-Pilko ◽  
Uwe Langsenlehner ◽  
Tatjana Stojakovic ◽  
Martin Pichler ◽  
Armin Gerger ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Cancer Patients ◽  
Fibrinogen Level ◽  
Plasma Fibrinogen ◽  
Plasma Fibrinogen Level ◽  
Breast Cancer Patients ◽  
Disease Specific

COVID-19 outcomes in patients with a history of breast cancer: A diverse multicenter Los Angeles cohort study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e12544-e12544
Author(s):  
Nikhita Kathuria-Prakash ◽  
Lauren Antrim ◽  
Alexander W Sun ◽  
Irene Kang ◽  
Maria De Lourdes Garcia-Jimenez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cohort Study ◽  
Los Angeles ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Hospitalization Rate ◽  
Breast Cancer Patients ◽  
Treatment History ◽  
History Of ◽  
Extent Of Disease

e12544 Background: Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has affected over 100 million individuals during the current pandemic. Cancer is a reported risk factor for worse outcomes from SARS-CoV-2 infection and its clinical syndrome COVID-19. However, risk associated with specific cancer subtypes, extent of disease, and treatment history remains unclear. Breast cancer is the most common cancer in women and is treated with multiple modalities that may affect COVID-19 severity and outcomes, including surgery, radiation (RT), hormone therapy (HT), and chemotherapy (CT). Methods: We conducted a retrospective cohort study of patients with SARS-CoV-2 and history of breast cancer at two academic centers in Los Angeles, CA between January – September, 2020. Demographic information, cancer diagnosis, treatment history, comorbid conditions, and clinical outcomes of COVID-19 were reviewed. The primary outcome was rate of hospitalization for COVID-19. Associations were evaluated for significance by chi-square test or Student’s T test, with a = 0.05. Results: Our cohort included 61 patients with history of breast cancer. 19 (31.1%) required hospitalization and 3 (4.9%) died from COVID-19. Median age was 61 years. 44% of patients were White/Caucasian, 37.7% Hispanic/Latinx, 8% Black/African American, 5% Asian, and 5% were of another race. 87% of patients had local or regional disease and 13% had distant metastases. 53% of patients had ever received CT historically, 66% HT, and 53% RT. 25% of patients received cancer treatment (surgery, CT, or RT) within 90 days of COVID-19 diagnosis. 38% were on HT at time of COVID-19 diagnosis. Patients with prior RT were more likely to be hospitalized from COVID-19 than those with no prior RT (44% vs 14%, p = 0.02), as were patients with 2 or more comorbidities (p = 0.01). In addition, there was a trend toward lower hospitalization rates for patients on HT [24% vs. 42% (p = 0.17)] and a trend toward higher hospitalization rate for non-white ethnicity [35% vs. 25% (p = ns)]. Extent of disease, history of CT, or receipt of any cancer treatment (e.g. surgery, RT, CT) within 90 days of COVID-19 diagnosis were not associated with hospitalization rate. Conclusions: In our diverse cohort of breast cancer patients with COVID-19 a history of RT and presence of multiple comorbidities were both associated with increased risk of hospitalization, while a history of HT was not. Further investigation is needed to validate these findings in larger cohorts. These findings may inform recommendations for breast cancer patients during the ongoing SARS-CoV-2 pandemic.

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients.

1996 ◽  
Vol 14 (5) ◽  
pp. 1581-1588 ◽  
Author(s):  
M Sandström ◽  
A Freijs ◽  
R Larsson ◽  
P Nygren ◽  
M L Fjällskog ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Half Life ◽  
Systemic Exposure ◽  
Compartment Model ◽  
Pharmacokinetic Parameters ◽  
Therapeutic Drug ◽  
Population Pharmacokinetic ◽  
Breast Cancer Patients ◽  
Nonlinear Elimination

PURPOSE The aim of this study was to investigate the covariance between the pharmacokinetics of the three components of the FEC regimen, epirubicin (EPI), fluorouracil (5-FU), and the cyclophosphamide (CP) metabolite 4-hydroxycyclophosphamide (4-OHCP), in breast cancer patients. PATIENTS AND METHODS Data from 21 women were collected over a total of 35 cycles. 5-FU (300 to 600 mg/m2) and CP (300 to 600 mg/m2) were administered as bolus injections, whereas EPI (15 to 60 mg/m2) was administered either as a bolus injection or as an infusion. The pharmacokinetics of the component drugs were monitored using a limited sampling scheme. Population pharmacokinetic models for each of the three drugs were developed using the program NONMEM. RESULTS The data for 5-FU were best described by a one-compartment model with nonlinear elimination, where the maximal rate of elimination (Vmax) and the concentration at which the elimination was half-maximal (Km) were 105 mg/L.h and 27 mg/L, respectively. EPI concentration-time profiles showed a triexponential decline, with a mean terminal half-life of 24 hours and a clearance (CL) of 59 L/h. The elimination of 4-OHCP was monoexponential, with a mean half-life of 7 hours. The interindividual coefficients of variation (CVs) in CL were 30%, 22%, and 41% for 5-FU, EPI, and 4-OHCP, respectively. The corresponding values for intrapatient course-to-course variability in CL were 11%, 8%, and 27%. No significant correlation in any of the pharmacokinetic parameters between the drugs was found. CONCLUSION Individualization of dosing of the FEC regimen using therapeutic drug monitoring and attempts to find concentration-response relationships may be successful, but requires that the exposure of all three drugs is considered simultaneously.

scholarly journals Assessment of Role of Platelet Aggregation in Metastatic Breast Cancer Patients

2022 ◽  
Vol 8 (1) ◽  
pp. 81-86
Author(s):  
Ashwini Ramji ◽  
Shanmugan C V
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Platelet Aggregation ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Normal Range ◽  
Group I ◽  
Group Ii

Background: To assess role of platelet aggregation in metastatic breast cancer patients.Methods:40 cases (Group I) of metastatic breast cancer patients and equal number of healthy control (Group II) subjects were included. Platelet aggregation studies in vitro using ADP and Thrombin were performed using an optical aggregometer. Detection of platelet aggregation was done by Chrono log series 490 dual and four channel optical aggregometer systems.Results:There were 4 subjects in group I and 12 in group II having ADP <60, 26 subjects in group I and 28 in group II with ADP 61-72 and 10 subjects in group I with ADP >72. Low thrombin <58 was seen in 8 in group II, normal thrombin between 61-72 was seen among 11 in group I and 32 in group II and high thrombin >82 among 29 in group I respectively. Amongst patients with normal platelet count, 14 patients had platelet aggregation with ADP in the normal range and 4 patients had platelet aggregation with ADP in the lower range. In patients with high platelet count, 12 showed aggregation in the normal range, and 10 patients showed aggregation in the higher range which was statistically significant (P< 0.05) (Table III, Graph II).Conclusion: Platelet aggregation has an important part to play in the tumor metastasis of breast cancer patients.

In Vivo Measurements of Fibrin Formation and Fibrinolysis in Operable Breast Cancer

1989 ◽  
Vol 61 (02) ◽  
pp. 318-321 ◽  
Author(s):  
P McCulloch ◽  
J Douglas ◽  
G D O Lowe ◽  
G Murray ◽  
W D George
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Degradation Products ◽  
Breast Disease ◽  
Breast Diseases ◽  
Breast Cancer Patients ◽  
Fibrin Formation ◽  
Er Positive ◽  
Malignant Breast

SummaryFibrin formation and fibrinolysis were estimated in 89 breast cancer patients by measurement in plasma of Fibrin Fragment Bβ 15-42 and Fibrinopeptide A (FPA), serum Fibrin(ogen) Degradation Products (FDPs) and plasminogen activator by Fibrin Plate Lysis Assay. Results were compared with (a) 26 patients with benign breast diseases; and (b) 45 healthy factory workers. FPA, FDP and Bβ 15-42 Levels were elevated in both breast cancer patients and benign disease patients, but there were no significant differences between these two groups. Cancer stage, patient age and smoking habits did not affect these results, but Oestrogen Receptor (ER) positive patients had higher Bβ 15-42 values than ER negative patients (p = 0.017). These results show that fibrin formation is enhanced preoperatively in patients with either benign or malignant breast disease. The fibrinolytic response to activated coagulation may be relatively deficient in breast cancer. The roles of malignancy, stress and other factors in the causation of these abnormalities require further assessment.

scholarly journals Are Thyroid Hormone and Tumor Cell Proliferation in Human Breast Cancers Positive for HER2 Associated?

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Iordanis Mourouzis ◽  
Alexandros Tzovaras ◽  
Basil Armonis ◽  
Alexandros Ardavanis ◽  
Maria Skondra ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Proliferation ◽  
Thyroid Hormone ◽  
Cancer Patients ◽  
Breast Cancers ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Normal Range ◽  
Her2 Breast Cancer ◽  
Er Positive

Objective.This study investigated whether thyroid hormone (TH) levels are correlated to cell proliferation (Ki67), in euthyroid breast cancer patients.Design and Methods.86 newly diagnosed breast cancer patients with estrogen receptor (ER) positive tumors, who referred for surgery, were included in the study.Results.FT3, FT4, and TSH were within normal range. No correlation was seen between Ki67 and FT3 (r=-0.17,P=0.15), FT4 (r=-0.13,P=0.25), or TSH (r=-0.10,P=0.39) in all patients studied. However, subgroup analysis showed that, in HER2(+) patients, a negative correlation existed between FT3 levels and Ki67 (r=-0.60andP=0.004) but not between Ki67 and FT4 (r=0.04andP=0.85) or TSH (r=-0.23andP=0.30). In HER2(−) patients, there was no significant correlation between Ki67 and FT3 (r=-0.06,P=0.67), FT4 (r=-0.15,P=0.26), or TSH (r=-0.09,P=0.49). Phospho-p44/total p44 ERK levels were found to be increased by 2-fold in HER2(+) versus HER2(−) tumors. No difference was detected in phospho-p42/total p42 ERK levels.Conclusions.TH profile is not altered in patients with newly diagnosed breast cancer. However, FT3 levels, even within normal range, are negatively correlated with cell proliferation in HER2(+) breast cancer tumors. This response may be due to the interaction between ERK and TH signaling.

Sign in / Sign up

Export Citation Format

Share Document